Generic Medicine Info
Indications and Dosage
Menopausal hormone replacement therapy, Prophylaxis of osteoporosis
Adult: 1.4-2.8 mg daily in a cyclical or continuous regimen, usually given with estradiol and estriol. Cyclical progestogen should be given for 12-14 days of each cycle in women with intact uterus.
Hypersensitivity; undiagnosed vaginal bleeding; thrombophlebitis or thromboembolic disorders; breast carcinoma except in selected patients being treated for metastatic disease; oestrogen-dependent tumor; porphyria; pregnancy.
Special Precautions
Conditions exacerbated by fluid retention; hypercalcaemia, CV and gallbladder disease; lipid effects; familial defects of lipoprotein metabolism. Children (premature closure of epiphyses). May increase BP, risk of venous thromboembolism, risk of breast cancer, size of preexisting uterine leiomyomata and risk of benign hepatic adenoma. Lactation. Vaginal tablet: Severe atrophic vaginal mucosa or following gynaecological surgery.
Adverse Reactions
GI disturbances, genitourinary changes, haematologic disorders, CV and CNS effects, endocrine and metabolic disorders, cholestatic jaundice, local skin reactions, chorea, contact lens intolerance, steeping of corneal curvature, pulmonary thromboembolism, carbohydrate intolerance.
Drug Interactions
Substrate of CYP1A2, 2A6, 2B6, 2C8/9, 2C19, 2D6, 2E1, 3A4; inhibits CYP1A2; induces CYP3A4. Effect decrease by rifampin, nelfinavir, ritonavir and anticonvulsants, folic acid.
Food Interaction
Black cohosh, dong quai, red clover, saw palmetto, ginseng, St. John's wort.
Lab Interference
Reduced response to metyrapone test. May interfere with thyroid function and glucose tolerance tests.
Mechanism of Action: Estrone is a naturally occurring steroidal oestrogen.
Store below 25°C.
MIMS Class
Oestrogens, Progesterones & Related Synthetic Drugs
Disclaimer: This information is independently developed by MIMS based on Estrone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in